Navigation Links
deCODE genetics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

f 2008, revenue was $42.0 million, compared to $27.1 million for the same period last year. As of September 30, 2008, the company had $17.7 million in deferred revenue that will be recognized over future reporting periods. The period-on-period increase in revenue for the third quarter and first nine months of 2008 was driven principally by growth in the company's genomic services business, which includes the company's diagnostics, deCODEme(TM) personal genome analysis, and contract genotyping businesses.

Research and development expense was $5.7 million for the third quarter of this year, compared to $14.1 million for the same period last year. For the first nine months of 2008, R&D expense was $26.3 million, compared to $41.3 million for the first nine months of 2007. Our research and development expense in the first nine months of this year reflects the conclusion of clinical pharmacology studies in our most advanced drug development programs, preparations for the IND filing for our PDE4 modulator DG071, the launch of our prostate cancer, glaucoma and breast cancer tests, and the advancement of gene and target discovery work in a range of major disease areas.

Selling, general and administrative expense for the third quarter of 2008 was $6.7 million, compared to $7.1 million for the 2007 period. For the first nine months of the year, SG&A expense was $21.0 million in 2008 and $19.4 million in 2007.

At September 30, 2008, the company had liquid funds available for operating activities (cash and cash equivalents together with current investments) of $11.8 million, as compared to $23.7 million at June 30, 2008 and $64.2 million at December 31, 2007. The net utilization of liquid funds in the three and nine-month periods ended September 30, 2008 was $12.0 million and $52.4 million, respectively. At September 30, 2008, the company had $35.5 million in cash, cash equivalents and investments, comprised of the $11.8 million in cash and cash equivalents
'/>"/>

SOURCE deCODE genetics Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE Launches deCODEme(TM)
5. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
6. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
7. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. deCODE Genetics Announces Full-year 2007 Financial Results
10. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
11. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... promotions as well as changes to Martine Rothblatt ... Promotions United Therapeutics announced the promotion ... Co-Chief Executive Officer and David Zaccardelli , Pharm.D. ... connection with these promotions, Dr. Rothblatt,s title will change ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... June 5, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) today ... of financing arrangements, including a $3 million investment already ... further funding on fixed, specified and favorable terms, at ... chooses.  This series of financing arrangements will provide a ...
... Recent biopharmaceutical product launches have produced both noteworthy failures ... with a continually evolving launch landscape, organizations are rethinking ... current launch environment. In a new ... and failure points facing new product launches, Best Practices, ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... financial results for the fourth quarter and full year of ... close in the US.   The Company will ... June 13, 2011 to discuss its financial performance and give ...
Cached Biology Technology:Northwest Biotherapeutics Announces Series of Financing Arrangements 2Northwest Biotherapeutics Announces Series of Financing Arrangements 3Northwest Biotherapeutics Announces Series of Financing Arrangements 4Creating a Road Map for Successful Cardiovascular New Product Launch 2China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Austin researchers have discovered how to extract and use information ... from the focus distance, a feat only accomplished by human ... camera, the human eye has an auto-focusing system, but human ... not require trial and error to focus an object. ...
... Texas Advanced Computing Center (TACC) at the University of ... and support a world-class supercomputer with comprehensive computing and ... Made possible by a $27.5 million grant from the ... of the NSF "eXtreme Digital" (XD) program, an integrating ...
... some people with asthma do not respond well to inhaled ... Researchers found that asthma patients who have two copies of ... steroid inhalers as those with two copies of the regular ... National Heart, Lung, and Blood Institute (NHLBI), part of the ...
Cached Biology News:Researchers develop optimal algorithm for determining focus error in eyes and cameras 2Stampede charges computational science forward in tackling complex societal challenges 2Stampede charges computational science forward in tackling complex societal challenges 3Stampede charges computational science forward in tackling complex societal challenges 4NIH-funded study connects gene variant to response to asthma drugs 2
Schneider's Drosophila - Insect medium...
... quick and easy operation of a wide ... The software is fully secure and ... Part 11 regulations, and compatible with user-created ... versatility enables use in high-level research and ...
... molecular weight of 16 kDa. Leptin is a ... adipocytes [1,2]. Leptin is thought to play a ... In the human, leptin levels are elevated with ... A relationship between serum leptin levels and several measures ...
... in this kit are prepared with pure ... Biochains Mitochondria Isolation Kit is designed to ... fast and easy way. One kit is ... isolations (enriching mitochondria from 10 20 ...
Biology Products: